Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ferriplex-500 is a parenteral iron supplement formulation developed and marketed by the Indian pharmaceutical company Unifaith Biotech. It contains ferrous ascorbate at a concentration of 50mg/mL and is typically administered as a 10 mL injection. The product is indicated for the treatment of iron deficiency anemia, particularly in patients who require rapid replenishment of iron stores or those who are unable to tolerate or respond to oral iron therapy. By providing bioavailable iron directly into the systemic circulation, Ferriplex-500 facilitates the synthesis of hemoglobin and helps restore normal erythropoiesis. It is positioned as a critical care solution within Unifaith Biotech's branded generic portfolio in the Indian market.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ferriplex-500.